


## AMENDMENTS TO THE CLAIMS

This list of claims replaces the claims in the application.

Claims 1-53 (canceled)

54. (currently amended) A compound having the structure IA



a prodrug of the compound, a pharmaceutically acceptable salt of the compound, a stereoisomer of the compound, a tautomer of the compound, or a solvate of the compound

wherein G is -C(O)-, =CR<sup>3</sup> or -CR<sup>3</sup>R<sup>4</sup>-;

wherein R<sup>3</sup> and R<sup>4</sup> are -H or one of R<sup>3</sup> and R<sup>4</sup> is -H and the other is -OH or substituted or unsubstituted lower alkoxy;

and the dashed lines in structure IA represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,6-diene, 1,7-diene, 1,8-diene, 1,15-diene, 4,8-diene, or a 3,16-diene within the fused four-ring system;

or G is -C(O)- or -CR<sup>3</sup>R<sup>4</sup>-;

wherein R<sup>3</sup> is -OH or substituted or unsubstituted lower alkoxy and R<sup>4</sup> is -H;


and the dashed lines in structure IA represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises 1,3-diene, or 1,5-diene within the fused four-ring system;

and K is -C(O)-, =CR<sup>1</sup>- or -CR<sup>1</sup>R<sup>2</sup>-, wherein R<sup>2</sup> is -H and R<sup>1</sup> is -OR<sup>11</sup>, wherein R<sup>11</sup> is -H, substituted or unsubstituted alkyl or -C(O)R<sup>12</sup>, wherein R<sup>12</sup> is substituted or unsubstituted lower alkyl;

A is -CR<sup>9</sup>R<sup>10</sup>- wherein R<sup>9</sup> is -OH or substituted or unsubstituted lower alkoxy and R<sup>10</sup> is substituted or unsubstituted lower alkyne.

55. (currently amended). The compound of claim 4 54, wherein the fused ring system is a 1,6-diene and G is =CR<sup>3</sup>-, wherein R<sup>3</sup> is -H, -OH, or substituted or unsubstituted lower alkoxy.

56. (currently amended) A The compound having the structure II of claim 54




~~a prodrug of the compound, a pharmaceutically acceptable salt of the compound, a stereoisomer of the compound, a tautomer of the compound, or a solvate of the compound~~

~~wherein the dashed lines in structure II IA represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,3-diene, or 1,5-diene within the fused four-ring system and G is -C(O)- or -CR<sup>3</sup>R<sup>4</sup>-.~~

57. (currently amended) The compound of claim 58, wherein the fused ring system is a 1,5-diene.

58. (currently amended) A compound having the structure IIA IB



IIA IB

wherein,

X and Y are -O- or -S-;


Z is optionally substituted C2-C4 alkyl;

each  $R^{11}$  is independently -H or  $C(O)R^{12}$ ; wherein  $R^{12}$  is lower alkyl;

and the dashed lines in structure IIA IB represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,3-diene, or 1,5-diene within the fused four-ring system.

59. (previously presented) The compound of claim 58, wherein both  $R^{11}$  are -C(O)-CH<sub>3</sub>; and the compound comprises a 1,5-diene within the fused four-ring system.

60. (currently amended) A The compound of claim 57 having the structure-



wherein G is -C(O)- or -CR<sup>3</sup>R<sup>4</sup>-, wherein R<sup>3</sup> is -H and R<sup>4</sup> is -OH.

61. (currently amended) A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and at least one compound of claims 54 or ~~claim 56~~ or 62.

62. (new) The compound of claim 57

wherein G is -CR<sup>3</sup>R<sup>4</sup>-, wherein R<sup>3</sup> is -H and R<sup>4</sup> is -OH;

K is -CR<sup>1</sup>R<sup>2</sup>-, wherein R<sup>1</sup> is -OR<sup>11</sup> wherein R<sup>11</sup> is -H or -C(O)R<sup>12</sup> wherein R<sup>12</sup> is unsubstituted lower alkyl; A is -CR<sup>9</sup>R<sup>10</sup>-, wherein R<sup>9</sup> is -H and R<sup>10</sup> is unsubstituted lower alkyne.

63. (new) The compound of claim 62 having the structure

